EuroNet-PHL-C2
Research type
Research Study
Full title
Second International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents
IRAS ID
181571
Contact name
Sean Jennings
Contact email
Sponsor organisation
Justus Liebig Universität Gießen
Eudract number
2012-004053-88
Clinicaltrials.gov Identifier
Duration of Study in the UK
11 years, 0 months, 0 days
Research summary
EuroNet-PHL-C2 Summary:
Survivorship for children with classical Hodgkin’s Lymphoma has improved greatly in recent years, but cure often comes at the expense of long-term health problems related to the treatment, particularly radiotherapy, which is known to cause secondary cancers, cardiac problems and other serious complications.
EuroNet-PHL-C2 seeks to optimise an individually tailored therapy for each Patient, effectively treating disease but avoiding over-treatment and thereby reducing late side-effects. The study aims to reduce numbers of Patients needing radiotherapy and minimise the extent of irradiation (compared to standard treatment) in those Patients where radiotherapy is required for effective treatment.
Chemotherapy requirements for each Patient are determined according to spread of disease and risk level defined by the study. The Patient radiotherapy requirements are evaluated by their treatment response after 2 cycles of initial chemotherapy and at the end of chemotherapy. Response to treatment is assessed by state-of-the-art imaging and an interpretation technique specific to EuroNet-PHL-C2 which provides a refined assessment of response and ensures that Patients only get radiotherapy when absolutely necessary.
In EuroNet-PHL-C2, a new more intensified consolidation chemotherapy regimen (which reduces the need for radiotherapy) is introduced for intermediate and high risk Patients and will be tested (by randomisation) against standard treatment.REC name
London - West London & GTAC Research Ethics Committee
REC reference
17/LO/1727
Date of REC Opinion
30 Oct 2017
REC opinion
Favourable Opinion